Peripheral Arterial Disease and Claudication

Atherosclerotic Disease Development

• Progressive buildup of lipid-rich plaques in medium and large arteries (aortoiliac, femoropopliteal, and tibioperoneal vessels) through oxidized LDL uptake by macrophages, smooth muscle proliferation, and connective tissue deposition
• Plaque rupture with subsequent thrombosis creates acute or progressive luminal narrowing, reducing arterial diameter and increasing flow resistance according to Poiseuille's law (resistance inversely proportional to radius⁴)
• Endothelial dysfunction precedes plaque formation, characterized by impaired nitric oxide (NO) production, increased reactive oxygen species, and enhanced leukocyte adhesion

Hemodynamic Consequences

• Critical stenosis occurs when arterial narrowing exceeds 70% luminal diameter (≥50% area reduction), at which point resting blood pressure gradients develop; stenosis >90% typically produces ischemic symptoms at rest
• Metabolic demand during exercise increases oxygen requirements 10-20 fold, but compromised arterial supply cannot meet increased flow demand, creating ischemic metabolic acidosis with lactate and H⁺ accumulation in skeletal muscle
• Collateral vessel recruitment through shear stress-mediated vasodilation partially compensates for proximal stenosis but remains insufficient during high metabolic demand

Muscle Ischemia and Symptom Generation

• Claudication pain results from ischemic metabolic byproduct accumulation (lactate, inorganic phosphate, hydrogen ions, ADP) stimulating nociceptors, with symptoms typically appearing when muscle oxygen delivery falls below 50% of demand
• Endothelial dysfunction impairs adenosine production and prostacyclin release, eliminating vasodilatory compensatory mechanisms normally engaged during exercise
• Chronic hypoxia triggers angiogenesis through HIF-1α and VEGF signaling in some patients, explaining variable symptom progression despite stable stenosis

Major Etiologic Factors

• Atherosclerosis accounts for >90% of PAD cases (primarily in lower extremities), with risk factor burden determining disease extent and progression
• Acute thromboembolism causing acute limb ischemia (distinct from chronic claudication); sources include cardiac (atrial fibrillation, left ventricular thrombus), arterial wall (atherosclerotic plaque rupture), or paradoxical embolism
• Thrombophilia and hypercoagulable states (protein C/S deficiency, antithrombin deficiency, Factor V Leiden, prothrombin G20210A mutation, antiphospholipid syndrome) predisposing to recurrent thrombosis, particularly in younger patients with claudication

Major Risk Factors (Dose-Dependent Relationship)

• Smoking: Most modifiable risk factor with 4-5 fold increased PAD risk; acceleration of atherosclerosis through endothelial damage, enhanced oxidative stress, and platelet aggregation
• Diabetes mellitus: 2-4 fold increased risk with propensity for distal disease (tibioperoneal involvement) and calcific arterial wall changes; impaired endothelial function and chronic inflammation
• Hypertension: Proportional PAD risk elevation; vessel wall shear stress promotes atherosclerosis and arterial remodeling
• Dyslipidemia: LDL particle accumulation and HDL deficiency; atherogenic particle composition (small, dense LDL) carries greater risk than elevated total cholesterol alone
• Age: Progressive prevalence with decade of life; male predominance 2-3:1 in younger cohorts, equalizing after age 75
• Chronic kidney disease: Estimated glomerular filtration rate <60 mL/min/1.73m² confers independent PAD risk through uremic factors, vascular calcification, and hypertension
• Inflammatory markers: Elevated C-reactive protein and inflammatory cytokines predict disease progression and cardiovascular events independent of traditional risk factors
• Elevated Lipoprotein(a): Lp(a) >50 mg/dL carries PAD risk equivalent to elevated LDL; poorly responsive to statins

Cardinal Symptoms

• Intermittent claudication: Reproducible lower extremity pain (calf most common, followed by buttock/hip, thigh, foot) triggered by predictable walking distance (claudication distance), resolving completely with 1-10 minutes rest; typically described as ache, heaviness, cramping, or "charley horse"; pathognomonic when reproducible with consistent exertion
• Rest pain: Indicates critical limb ischemia from severe stenosis; severe burning foot pain occurring at night, often worse in supine position and relieved by leg dependency (sleeping in chair or dangling leg over bed)
• Acute limb ischemia: Sudden-onset severe pain, pallor, pulselessness, paresthesias, paralysis (6 Ps: Pain, Pallor, Pulselessness, Paresthesias, Paralysis, Poikilothermia); medical emergency requiring immediate intervention

Physical Examination Findings

• Absent or diminished pulses: Decreased femoral, popliteal, dorsalis pedis, or posterior tibial pulses (absent pulse suggests >50% stenosis at that level); asymmetric pulses highly specific for PAD
• Bruits: Audible systolic bruits over femoral arteries indicate turbulent flow from significant stenosis
• Skin changes: Pallor with elevation (indicates severe ischemia), dependent rubor/cyanosis (reactive hyperemia with leg dependency in critical ischemia), thin shiny atrophic skin, hair loss on dorsal feet and lower legs
• Cool extremities: Reduced skin temperature compared to contralateral side; in severe disease, mottled or cyanotic appearance
• Ulceration or gangrene: Ischemic ulcers typically located on toes, heels, or lateral foot with punched-out borders and minimal granulation; black necrotic eschar indicates irreversible tissue loss
• Capillary refill delay: Prolonged blanching time on nail beds (>2 seconds) suggests impaired perfusion

Symptom Severity Classification

• Asymptomatic PAD: Arterial stenosis without claudication or ischemic rest pain; often identified incidentally on imaging or through abnormal ankle-brachial index
• Intermittent claudication: Reproducible ischemic pain with exertion (Fontaine stage II)
• Critical limb ischemia: Rest pain, tissue loss, or gangrene indicating inadequate perfusion at rest (Fontaine stages III-IV)

Ankle-Brachial Index (ABI) - First-Line Test

• Method: Systolic blood pressures measured in bilateral arms and ankles (dorsalis pedis and posterior tibial) using Doppler ultrasound; ABI = (ankle systolic / arm systolic)
• Interpretation:
• Normal: ABI 1.0-1.4
• Borderline: ABI 0.91-0.99 (suggests mild disease)
• Mild-to-moderate PAD: ABI 0.71-0.90 (claudication typical at this level)
• Moderate-to-severe PAD: ABI 0.41-0.70 (rest pain possible)
• Severe PAD: ABI ≤0.40 (critical limb ischemia)
• ABI >1.4: Suggests arterial wall calcification (medial sclerosis), limiting utility; warrants further imaging
• Sensitivity/Specificity: ~95% sensitivity and ~99% specificity for hemodynamically significant PAD (>50% stenosis) when claudication present; lower sensitivity in asymptomatic disease
• Limitations: Overestimates ABI in calcified vessels; may be falsely elevated in acute thrombosis before collateral development

Vascular Duplex Ultrasonography

• Method: B-mode imaging combined with Doppler flow assessment to visualize stenosis and measure peak systolic velocity (PSV)
• Interpretation:
• Normal artery: PSV <100 cm/s, continuous Doppler signal
• <50% stenosis: PSV <100 cm/s with normal spectral waveform
• 50-99% stenosis: PSV ≥100 cm/s with increased diastolic velocity and turbulent waveform
• Occlusion: Absent Doppler signal
• Advantages: No radiation, no contrast, excellent for initial assessment; operator-dependent
• Use: First imaging modality for claudication; maps vessel patency for surgical planning

CT or MR Angiography

• CT angiography: High sensitivity (94-98%) and specificity (90-95%) for detecting stenosis >50%; rapid acquisition; limited by contrast nephropathy risk; radiation exposure
• MR angiography: Non-contrast options (time-of-flight) available for renal disease; gadolinium-enhanced superior for vessel detail but requires gadolinium; slightly lower specificity for calcified lesions
• Use: When duplex inconclusive, before intervention planning, or comprehensive arterial mapping

Laboratory Findings

• Lipid panel: Total cholesterol, LDL, HDL, triglycerides; assess for dyslipidemia as PAD risk factor
• Fasting glucose or HbA₁c: Screen for diabetes in all PAD patients
• Renal function: Serum creatinine and eGFR; PAD patients have high CKD prevalence, influencing treatment decisions (contrast exposure risk)
• Complete blood count: Evaluate for anemia, elevated white blood cell count (inflammatory marker)
• Coagulation studies: Prothrombin time, activated partial thromboplastin time, CBC; consider hypercoagulability workup in young claudicants or atypical presentations

Diagnostic Criteria

• Claudication diagnosis: Reproducible lower extremity pain with walking a specific distance, complete relief with rest, plus abnormal ABI or imaging confirmation
• Critical limb ischemia: Rest pain requiring opioid analgesia for >2 weeks OR tissue loss (ulceration/gangrene) with ABI ≤0.4 or toe pressure <30 mmHg

Risk Factor Modification (Foundation for All PAD Patients)

• Smoking cessation: Most impactful intervention reducing claudication progression 25-50%; reduces cardiovascular event rate 30-50%; utilize counseling, nicotine replacement, varenicline (Chantix), or bupropion
• Blood pressure control: Target <140/90 mmHg (or individualized based on tolerance); reduce risk of stroke and MI in PAD cohort; use ACE inhibitors or ARBs preferentially
• LDL cholesterol: Target <70 mg/dL (or <55 mg/dL for very high-risk); mandatory high-intensity statins (atorvastatin 80 mg daily or rosuvastatin 40 mg daily); add ezetimibe 10 mg daily or PCSK9 inhibitors if LDL >70 after statin monotherapy; benefits beyond lipid lowering through anti-inflammatory and plaque stabilization effects
• Glycemic control: Target HbA₁c <7% in most diabetic PAD patients; reduces microvascular complications though limited evidence for macrovascular PAD benefit; individualize targets in elderly
• Weight management: Target BMI 18.5-24.9 kg/m²; obesity increases claudication severity and cardiovascular risk

Antiplatelet Therapy - Cornerstone Medical Treatment

• Aspirin: 81-325 mg daily reduces cardiovascular event rates (MI, stroke, cardiovascular death) by ~20% in PAD; first-line for claudication management; use indefinitely unless contraindication
• P2Y₁₂ inhibitors: Clopidogrel (Plavix) 600 mg loading followed by 75 mg daily superior to aspirin for cardiovascular event reduction in PAD (NNT=67 to prevent one event over 2 years); reserved for claudicants intolerant of or with recurrent events on aspirin; causes thrombotic thrombocytopenic purpura rarely
• Dual antiplatelet therapy: Generally reserved for acute coronary syndrome or after stent placement; increased bleeding risk without documented PAD-specific benefit

Symptomatic Claudication Treatment

• Supervised exercise therapy: Most effective non-pharmacologic treatment; treadmill or track walking 3 times weekly for 30-45 minutes improves claudication distance 50-200% through enhanced collateral development, improved endothelial function, and increased muscle oxidative capacity; requires 3-6 month commitment; benefits plateau at 6 months
• Cilostazol: Phosphodiesterase-3 inhibitor; 100 mg twice daily (50 mg if CrCl <30 mL/min) increases claudication distance 40-60% through vasodilation and antiplatelet effects; contraindicated in heart failure (worsens mortality); modest effect but adjunctive option when exercise insufficient
• Pentoxifylline: 400 mg three times daily improves blood rheology; modest claudication improvement (20-30%); inferior to cilostazol; used in limited settings due to weak efficacy
• Statins: Pleiotropic benefits beyond LDL lowering; reduce claudication progression and promote symptom improvement through anti-inflammatory and endothelial protective effects

Revascularization - Indication-Specific Strategy

• Timing: Reserve for claudication only when symptoms severely limit quality of life despite supervised exercise and medical optimization (controversial; individualized decision); revascularization does not reduce cardiovascular event rates
• Indications for intervention:
• Aortoiliac disease: Excellent outcomes; percutaneous transluminal angioplasty (PTA) with stent 5-year patency 70-80%; consider aortofemoral bypass if extensive disease or stent failure (5-year patency 85-90%)
• Femoropopliteal disease: Moderate outcomes; endovascular intervention (PTA ± stent) 1-year patency 60-70%, 5-year patency 40-50%; femoropopliteal bypass with vein preferred (5-year patency 70-80%) versus prosthetic (5-year patency 50-60%)
• Tibioperoneal disease: Poor outcomes with endovascular; reserved for critical limb ischemia; bypass preferred but limited vessels; consider free tissue transfer if no suitable targets
• Critical limb ischemia revascularization: Mandatory intervention to prevent amputation; goal is hemodynamic improvement, not necessarily complete stenosis resolution
• Endovascular first: Current standard approach for most lesions given lower morbidity; reserve surgical bypass for endovascular failure or anatomic unsuitability

Acute Limb Ischemia Management

• Immediate anticoagulation: Unfractionated heparin IV bolus 80 units/kg immediately to prevent thrombus propagation
• Imaging: Emergent CT or MR angiography to delineate anatomy; duplex acceptable if rapid access
• Revascularization: Within 6 hours for salvage (viable limb without sensory/motor loss); endovascular thrombolysis (urokinase or alteplase) preferred for early intervention (<14 days symptom onset); surgical embolectomy if unable to tolerate lytic therapy or contraindication
• Amputation: Inevitable if irreversible tissue damage (sensory loss, motor paralysis >6 hours, established gangrene)

Monitoring and Follow-Up

• Clinical assessment: Serial A

Limb complications

• Progression to chronic limb-threatening ischemia (CLTI): perfusion falls below resting metabolic demand, so nutrient flow cannot sustain skin integrity; signaled by rest pain relieved by dependency, non-healing ulcer, or gangrene with ABI at the severe end of the scale or very low toe pressure. Requires urgent vascular referral for revascularization — limb loss is the alternative.
• Acute limb ischemia superimposed on chronic stenosis (in-situ thrombosis of a stenotic segment, plaque rupture, or cardioembolism): the 6 Ps, with loss of sensation or motor power marking a threatened limb. Surgical/vascular emergency — heparinize and revascularize. Irreversible skeletal muscle injury typically begins after roughly 4–6 hours of complete ischemia, but tolerance varies with collateral supply; urgency is actually driven by the Rutherford categories (viable, marginally threatened, immediately threatened, irreversible), which grade sensory loss, motor deficit, and Doppler signals.
• Reperfusion injury after revascularization: return of flow into ischemic muscle releases K⁺, myoglobin, and acid, and capillary leak raises intracompartmental pressure. Look for compartment syndrome (pain out of proportion, tense compartment, pain on passive stretch) plus rhabdomyolysis, hyperkalemia, and acute kidney injury — both are emergencies; fasciotomy is limb-saving and the compartment pressure is measured only if the diagnosis is unclear.
• Ischemic ulcer infection, wet gangrene, and osteomyelitis: hypoperfused tissue cannot deliver leukocytes or antibiotics; fever, spreading erythema, crepitus, or purulence signal deep infection. Necrotizing soft-tissue infection or sepsis mandates emergent debridement/amputation, not observation.

Systemic and treatment-related complications

• Myocardial infarction, stroke, and cardiovascular death: PAD reflects diffuse atherosclerosis and is the dominant cause of mortality, exceeding limb events. ACC/AHA PAD guidance therefore treats every PAD patient as high cardiovascular risk with statin plus antiplatelet therapy.
• Bleeding: additive with dual antiplatelet therapy or with low-dose rivaroxaban added to aspirin; GI bleeding and intracranial hemorrhage are the events to weigh against ischemic benefit.
• Cilostazol in heart failure: contraindicated in heart failure of any severity per FDA labeling — not restricted to reduced ejection fraction. The rationale is that oral PDE-3 inhibitors (milrinone) increased mortality in chronic heart failure.
• Contrast-associated nephropathy and cholesterol (atheroembolic) embolization after angiography: catheter-scraped plaque showers distally, producing blue toe syndrome, livedo reticularis with palpable pulses, eosinophilia, and rising creatinine.
• Restenosis or graft/stent thrombosis: neointimal hyperplasia causes recurrent claudication at the prior threshold, detected by falling surveillance ABI or duplex velocities.

• ABI is always the first test: a patient with exertional calf pain relieved by rest gets a resting ankle-brachial index before any imaging. Duplex, CTA, or MRA are for planning intervention, not for making the diagnosis.
• ABI >1.4 means noncompressible, medially calcified vessels — not a normal result: classically in diabetes or ESRD (Mönckeberg medial sclerosis). Next step is a toe-brachial index (digital arteries are spared) or pulse volume recordings. If symptoms are classic but resting ABI is normal, order an exercise treadmill ABI — a post-exercise drop unmasks disease.
• Supervised exercise therapy is first-line for claudication, per ACC/AHA PAD guidance. It improves treadmill walking performance at least as much as, and in some trials more than, endovascular revascularization, though revascularization may yield greater disease-specific quality-of-life gains; the two are complementary. Mechanism: collateral recruitment, improved endothelial NO signaling, and greater muscle oxidative capacity.
• Cilostazol is contraindicated in heart failure of any severity (FDA contraindication, not limited to reduced EF) — the single most tested drug fact here. Supporting rationale: oral PDE-3 inhibitors such as milrinone increased mortality in chronic heart failure. Any stem pairing claudication with an S3, low EF, prior HF admission, or preserved-EF heart failure is testing this.
• Lipid and antiplatelet therapy: statin therapy is indicated in all patients with PAD, since PAD is clinical ASCVD. Antiplatelet monotherapy is a Class 1 recommendation in symptomatic PAD, reasonable (Class IIa) in asymptomatic PAD with ABI ≤0.90, and of uncertain benefit with borderline ABI 0.91–0.99. Revascularization relieves symptoms; it does not reduce MI or stroke.
• Smoking cessation is the highest-yield modifiable intervention, slowing progression to CLTI and amputation more than any drug.
• Leriche syndrome = aortoiliac occlusive disease with the triad of buttock/thigh claudication, absent femoral pulses, and erectile dysfunction.
• Distractor to avoid — pseudoclaudication from lumbar spinal stenosis: pain is positional, provoked by standing upright, relieved by sitting or leaning forward (shopping-cart sign), with normal pulses and normal ABI; true claudication is relieved by standing still. A second classic distractor: beta blockers are not contraindicated in PAD and should not be stopped when otherwise indicated.
• Acute limb ischemia (6 Ps): give IV unfractionated heparin immediately, then image and revascularize — do not delay anticoagulation for the angiogram.